Skip to content

LEAH Labs

YC W19 · Active · Living therapies for pets first, and their people next

Competitors

Adjacent

Also from W19

All of W19

About LEAH Labs

LEAH Labs is building living therapies for pets first, and their people next. We're first focused on CAR-T cell therapy for dogs with B cell lymphoma, the naturally occurring clinical analog of human non-Hodgkin's lymphoma. CAR-T cells are curative in humans, and our early results are showing the same - we're inducing remissions in pets with late stage lymphomas. Our virus-free gene editing platform allows us to engineer a dose of CAR-T cell therapy for ~$500, and brings the promise of a curative outcome. Given our safety and efficacy data to date, we believe this product could be used by general practice veterinarians, meaning we have thousands of customers all across the USA who typically treat with palliative care or refer cancer patients to specialty oncologists. Our CAR-T cell platform is regulated by the USDA, not the FDA, affording us a cost effective "full stack" to iterate and innovate on CAR-T cell therapy from a hypothesis through clinical validation.

YC batch
W19 · Winter 2019
Status, per YC
Active
Category
Other
Team size
4
Location
Minneapolis, MN, USA
Checked
35m ago

YC tags: CRISPR, Cell Therapy, Drug discovery

LEAH Labs in W19: 194 companies, 26% AI

LEAH Labs: questions

Which YC batch was LEAH Labs in?

LEAH Labs was in Y Combinator's Winter 2019 batch (W19).

Is LEAH Labs still active?

Y Combinator lists LEAH Labs as active.

Where is LEAH Labs based?

LEAH Labs lists Minneapolis, MN, USA as its location on YC's directory.

Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.

New startups by email

Mondays: new YC data, AI and devtools companies and status changes, only when something changed.

Double opt-in. Unsubscribe any time.